The Latest Cardiac and Vascular News
LONDON, May 16, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its first quarter ended March 31, 2023. First quarter 2023 revenues of $22.2 million. Cost reduction programs implemented across the global organization resulting in declining operating […]
LONDON, April 24, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX)(the “Company”) today announced that it has received notification (the “Notification”) from The Nasdaq Stock Market LLC that it is not in compliance with the minimum bid price requirement in Nasdaq Listing Rule 5450(a)(1) for continued listing on the Nasdaq […]
LONDON, March 21, 2023 (GLOBE NEWSWIRE) — LumiraDx Limited (NASDAQ: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial results for its fourth quarter and full year ended December 31, 2022. Full year 2022 revenues of $254.5 million. Q4 2022 revenue of $41.1 million compared to Q3 […]
Progress on Near-Term Growth Opportunities and Cost Savings LONDON, Nov. 09, 2022 (GLOBE NEWSWIRE) — LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced operational and financial results for the third quarter ended September 30, 2022. Q3 2022 revenue of $42.2 million compared to Q2 […]
The LumiraDx NT-proBNP and the LumiraDx D-Dimer tests are currently the only quantitative direct fingerstick assays produced for each test. Run on the highly portable LumiraDx Platform, they are designed for near-patient testing with connected results in 12 minutes and 6 minutes, respectively The LumiraDx NT-proBNP test is a rapid microfluidic […]
